NBT Bank N.A. Acquires New Shares in Amgen Inc. $AMGN

NBT Bank N.A. bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,874 shares of the medical research company’s stock, valued at approximately $1,633,000.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. State Street Corp lifted its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after purchasing an additional 605,928 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Amgen during the second quarter valued at $1,831,903,000. Finally, Amundi boosted its position in shares of Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after buying an additional 512,883 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is currently owned by insiders.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
• Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
• Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
• Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

Amgen Stock Performance

Shares of AMGN opened at $439.26 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a one year low of $288.00 and a one year high of $450.98. The firm has a market capitalization of $237.48 billion, a P/E ratio of 27.30, a PEG ratio of 3.28 and a beta of 0.41. The business has a fifty day moving average of $417.70 and a 200 day moving average of $377.83.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AMGN. Scotiabank boosted their target price on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Mizuho raised their price target on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Cantor Fitzgerald raised their price target on shares of Amgen from $400.00 to $440.00 and gave the company a “neutral” rating in a report on Monday, October 5th. Bank of America lifted their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Finally, UBS Group boosted their price objective on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $389.71.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.